Cobicistat: a new opportunity in the treatment of HIV disease?

Bibliography

• Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010;87:322-9
   PubMed Web of Science ®Google Scholar
• Xu L, Liu H, Murray B, et al. Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett 2010;1:209-13
   PubMed Web of Science ®Google Scholar
• Temesgen Z. Cobicistat, a pharmacoenhancer for HIV treatments. Drugs Today (Barc) 2013;49(4):233-7
   PubMed Web of Science ®Google Scholar
• Lepist EI, Phan TK, Anupma R, et al. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother 2012;56(10):5409-13
   PubMed Web of Science ®Google Scholar
• Stray KM, Bam RA, Birkus G, et al. Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir. Antimicrob Agents Chemother 2013;57(10):4982-9
   PubMed Web of Science ®Google Scholar
• Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002572/WC500153014.pdf
   Google Scholar
• Mathias A, Koziara J, Wei L, et al. Effect of acid reducing agents on the relative bioavailability and pharmacokinetics of cobicistat-boosted elvitegravir [abstract P_13]. 12th International Workshop on Clinical Pharmacology of HIV Therapy; 13 – 15 April 2011; Miami, FL
   Google Scholar
• Custodio JM, Gordi T, Kearney BP, Ramanathan S. Population pharmacokinetic of Cobicistat in adult healthy subjects and HIV-infected patients. Poster P36, 14th International Workshop on Clinical Pharmacology of HIV therapy; 22 – 24 April 2013; Amsterdam, The Nederlands
   Google Scholar
• German P, Warren D, West S, et al. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr 2010;55:323-9
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Wei X, Custodio J, et al. Pharmacokinetics of a novel EVG/COBI/FTC/GS-7340 single tablet regimen [abstract O-13]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 2012. Virology Education B.V., Utrecht, The Netherlands
   Google Scholar
• Kakuda TN, Opsomer M, Timmers M, et al. Bioavailability of two FDC formulations od darunavir/cobicistat 800/150 mg compared with darunavir/ritonavir 800/100mg co-administered as single agents [abstract O_20]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; April 2012; Barcelona, Spain
   Google Scholar
• Kakuda TN, Opsomer M, Timmers M, et al. Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers. J Clin Pharmacol 2014. [ Epub ahead of print]
   Google Scholar
• Ramanathan S, Wang H, Szwarcberg J, et al. Safety/tolerability, pharmacokinetics and boosting of twice-daily cobicistat administered alone or in combination with darunavir or tipranavir [abstract P_08]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; April 2012; Barcelona, Spain
   Google Scholar
• Ramanathan S, Warren D, Wei L, Kearney BP. Pharmacokinetic boosting of atazanavir with the pharmacoenhancer GS-9350 versus ritonavir [abstract 614]. Presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 12 – 15 September 2009; San Francisco, California
   Google Scholar
• Ramanathan S, Wang H, Stondell T, et al. Pharmacokinetics and drug interaction profile of cobicistat-boosted EVG with atazanavir, rosuvastatin, or rifabutin [abstract O-03]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; April 2012; Barcelona, Spain
   Google Scholar
• Bruce RD, Winkle P, Custodio JM, et al. Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance. Antimicrob Agents Chemother 2013;57(12):6154-7
   PubMed Web of Science ®Google Scholar
• Bruce RD, Winkle P, Custodio JM, et al. The phamacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. J Acquir Immune Defic Syndr 2013;63(4):480-4
   PubMed Web of Science ®Google Scholar
• Gallant JE, Koenig E, Andrade-Villanueva J, et al. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis 2013;208(1):32-9
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/study/NCT01837719
   Google Scholar
• Elion R, Cohen C, Gathe J, et al. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS 2011;25(15):1881-6
   PubMed Web of Science ®Google Scholar
• Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011;25:F7-12
   PubMed Web of Science ®Google Scholar
• Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012;379:2439-48
   PubMed Web of Science ®Google Scholar
• Zolopa A, Sax PE, DeJesus E, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013;63:96-100
   PubMed Web of Science ®Google Scholar
• Wohl DA, Cohen C, Gallant JE, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr 2014;65(3):e118-20
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, DeJesus E, Henry K, et al. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013;62(5):483-6
   PubMed Web of Science ®Google Scholar
• DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012;379(9835):2429-38
   PubMed Web of Science ®Google Scholar
• Clumeck N, Molina JM, Henry K, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr 2014;65(3):e121-4
   PubMed Web of Science ®Google Scholar
• German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr 2012;61:32-40
   PubMed Web of Science ®Google Scholar
• German P, Wei X, Mizuno V, et al. Pharmacokinetics of elvitegravir and cobicistat in subjects with severe renal impairment. 13th HIV Clinical Pharmacology Intl Workshop; 16 – 18 April 2012; Barcelona, Spain
   Google Scholar
• Custodio JM, Rhee M, Shen G, et al. Pharmacokinetics and safety of boosted-elvitegravir in subjects with hepatic impairment. Antimicrob Agents Chemother 2014;58(5):2564-9
   PubMed Web of Science ®Google Scholar
• Juday T, Correll T, Anene A, et al. Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US. Clinicoecon Outcomes Res 2013;5:437-45
   PubMedGoogle Scholar
• Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf [Accessed on 23 April 2014]
   Google Scholar
• Available from: http://www.eacsociety.org/Portals/0/Guidelines_Online_131014.pdf [Accessed on 23 April 2014]
   Google Scholar
• Available from: http://www.janssenrnd.com/sites/default/files/pdf/GLIDE_US_FDA_Filing_Press_Release_FINAL_040114.pdf#zoom=125
   Google Scholar
• Available from: http://news.bms.com/press-release/bristol-myers-squibb-submits-new-drug-application-us-fda-fixed-dose-combination-tablet [Accessed on 23 April 2014]
   Google Scholar